Home Tools
Log in
Cart

Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No. Product name CAS No. Purity Chemical Structure
T37535 Camrelizumab 1798286-48-2 98.6%
Camrelizumab
Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up ...
T9903 Avelumab 1537032-82-8 98.30%
Avelumab
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.
T9915 Eculizumab 219685-50-4 98.20%
Eculizumab
Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5
T9901 Adalimumab 331731-18-1 98.00%
Adalimumab
Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
T9909 Pertuzumab 380610-27-5 98.00%
Pertuzumab
Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 t...
T9924 Obinutuzumab 949142-50-1 98.00%
Obinutuzumab
Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
T12177 Natalizumab 189261-10-7 98.00%
Natalizumab
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
T9905 Cetuximab 205923-56-4 98.00%
Cetuximab
Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, ...
T9907 Nivolumab 946414-94-4 98%
Nivolumab
Nivolumab (anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell...
T76795 Xentuzumab 1417158-65-6 95.21%
Xentuzumab
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activ...
T9902 Atezolizumab 1380723-44-3 95.10%
Atezolizumab
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD...
T13666 Dupilumab 1190264-60-8 95.00%
Dupilumab
Dupilumab (REGN-668) is a systemic immunomodulator for AD. Dupilumab is a fully human monoclonal antibody against the alpha subunit of the interleukin-4 receptor...
T76792 Sibrotuzumab 216669-97-5 95.00%
Sibrotuzumab
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP).Sibrotuzumab is used in the study of colorectal cance...
T76830 Teneliximab 299423-37-3 95.00%
Teneliximab
Teneliximab (Chi220) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interact...
T38105 Ixekizumab 1143503-69-8 95.00%
Ixekizumab
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab bloc...
T35394 Sintilimab (anti-PD-1) 2072873-06-2 95%
Sintilimab (anti-PD-1)
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding ...
T9912 Trastuzumab 180288-69-1
Trastuzumab
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER...
T9919 Alemtuzumab 216503-57-0
Alemtuzumab
Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.
T9913 Ustekinumab 815610-63-0
Ustekinumab
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
T9926 Omalizumab 242138-07-4
Omalizumab
Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE)
Camrelizumab
T37535
Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up ...
Avelumab
T9903
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.
Eculizumab
T9915
Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5
Adalimumab
T9901
Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.
Pertuzumab
T9909
Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 t...
Obinutuzumab
T9924
Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
Natalizumab
T12177
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
Cetuximab
T9905
Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, ...
Nivolumab
T9907
Nivolumab (anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell...
Xentuzumab
T76795
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activ...
Atezolizumab
T9902
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD...
Dupilumab
T13666
Dupilumab (REGN-668) is a systemic immunomodulator for AD. Dupilumab is a fully human monoclonal antibody against the alpha subunit of the interleukin-4 receptor...
Sibrotuzumab
T76792
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP).Sibrotuzumab is used in the study of colorectal cance...
Teneliximab
T76830
Teneliximab (Chi220) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interact...
Ixekizumab
T38105
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab bloc...
Sintilimab (anti-PD-1)
T35394
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding ...
Trastuzumab
T9912
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER...
Alemtuzumab
T9919
Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.
Ustekinumab
T9913
Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
Omalizumab
T9926
Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE)
1 2 3 4 5 6 7 8 9 10 11 12
TargetMol